Biotech News

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

Rigel Pharmaceuticals (RIGL)Rigel PharmaceuticalsEarnings

, /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com . The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com .

Contact for Investors & Media: Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected]

Media: David Rosen Argot Partners Phone: 646.461.6387 Email: [email protected]

View original content to download multimedia: https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results-302835770.html

SOURCE Rigel Pharmaceuticals, Inc.

Open original release

Related news

Rigel Pharmaceuticals

Rigel Pharmaceuticals is a specialty pharmaceutical company with a commercial focus in hematology, inflammation, and related rare-disease settings. Its business combines marketed products with selective pipeline work.

Recent company news

Stock data

Close
37.39 USD
Market cap
555.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States